Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL By Ogkologos - August 6, 2026 172 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BRUIN CLL-322 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic... August 3, 2020 TMB Consortium Develops a TMB Calibration Tool October 13, 2021 Targeted drug recommended to treat some advanced lung cancer patients November 25, 2021 When Cancer Isn’t Your Only Challenge: How I Learned to Cope March 24, 2022 Load more HOT NEWS When You and Your Child Have VHL: 8 Ways to Cope ESMO Calls on the European Commission to Fund Cancer Research and... ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... How to Support a Spouse or Partner During Cancer Treatment by...
